Marker Therapeutics (MRKR) Amortization - Intangibles (2013)
Marker Therapeutics' (MRKR) quarterly Amortization - Intangibles came in at -$104000.0 in Q3 2013.
Powered by 
Analysis
Marker Therapeutics (MRKR) Amortization - Intangibles (2013) Analysis & Trends
Marker Therapeutics (MRKR) has reported Amortization - Intangibles for 1 consecutive years, with -$104000.0 the latest figure, recorded in Q3 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Marker Therapeutics | 23.37 Mn | 11.44 Mn | - |